Part of Cedars-Sinai Health System
Clinical Trials
449
67 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1902
Active, not recruiting
26
5.8%
Completed
184
41.0%
Enrolling By Invitation
14
3.1%
Not yet recruiting
27
6.0%
Recruiting
76
16.9%
Suspended
2
0.5%
Terminated
52
11.6%
Unknown
33
7.3%
Withdrawn
35
7.8%
No approval data available
- The Foundation for Sarcoidosis Research (FSR) announced 13 inaugural clinical sites for its national FSR Clinical Data Registry, including Brigham and Women's Hospital, Stanford, Yale, and Duke University. - The longitudinal, multi-center registry aims to improve understanding of sarcoidosis through standardized data collection across geographically and ethnically diverse patient populations. - FSR spent two years developing the protocol with input from patients, caregivers, clinicians, and pharmaceutical partners to address the disease's multi-disciplinary nature. - The registry will complement the existing FSR-SARC Patient Registry, creating a comprehensive resource to advance diagnosis, biomarker discovery, therapy assessment, and patient outcomes.
- A single-arm phase I trial combining oral l-glutamine with gemcitabine and nab-paclitaxel (GA) in 16 advanced pancreatic ductal adenocarcinoma (PDAC) patients achieved a 44% objective response rate, including two complete responses. - The recommended phase 2 dose was established at 30 g/day oral l-glutamine with full standard doses of gemcitabine (1,000 mg/m²) and nab-paclitaxel (125 mg/m²), with manageable toxicity and no treatment-related discontinuations. - Median overall survival reached 22 months with a 12-month OS rate of 69%, substantially exceeding the historical median OS of 258 days for first-line GA alone in metastatic PDAC. - Correlative analyses showed l-glutamine improved gut barrier function, reduced circulating lipopolysaccharide levels, and lowered proinflammatory cytokines (CCL11 and IL-33) in responders, supporting further randomized testing.
- A prospective study of over 350,000 UK Biobank participants found that drinking 5 or more cups of coffee daily was associated with a 32% lower risk of cirrhosis, 47% lower risk of liver cancer, and 42% lower risk of liver-related death over 13 years. - Both caffeinated and decaffeinated coffee showed protective associations, suggesting non-caffeine bioactive compounds such as polyphenols and chlorogenic acids may drive the benefits. - MRI and blood proteomic analyses revealed coffee drinkers had lower liver fat, reduced liver iron, lower fibroinflammation markers, and healthier liver protein profiles, providing biological plausibility. - Researchers caution the findings are observational and cannot prove causation, advising that coffee should complement—not replace—fundamental liver-healthy behaviors like limiting alcohol and maintaining a healthy weight.
- Jennifer Van Eyk's team at Cedars-Sinai has identified at least two distinct cardiomyocyte subpopulations in the human left ventricle using single-cell proteomics, with differences driven by sarcomeric proteins and metabolism. - Only one of these cardiomyocyte subpopulations responded to drug treatment, suggesting that drug failures in clinical trials may stem from cells being in a non-responsive state rather than the drug missing its target. - Single-cell proteomics revealed that mutant and wild-type proteins are not uniformly distributed among cells in individuals carrying sarcomeric mutations, potentially explaining why patients with identical mutations have vastly different clinical outcomes. - Van Eyk emphasizes that proteomics has reached a mature stage with high throughput, low cost, and remarkable precision, though biological interpretation of the vast protein data remains the field's greatest challenge.
- OpenAI's latest free model, GPT-5.5 Instant, scored better than physician-written answers on HealthBench, a benchmark developed with over 260 physicians to evaluate AI health capabilities. - More than 230 million people globally use ChatGPT for health and wellness queries weekly, making healthcare one of OpenAI's most important verticals according to health strategy lead Nate Gross. - A Nature Medicine study of ChatGPT Health found it failed to recommend hospital visits when medically necessary in over half of cases, though OpenAI disputed the methodology. - OpenAI has partnered with eight major health systems including Cedars-Sinai and HCA Healthcare, while Labcorp launched an AI-powered app using OpenAI's models for lab result interpretation.
- Erectile dysfunction affects over half of men over 40 and can precede major cardiovascular events by an average of three to five years, serving as an early warning signal. - Men with ED have a 59% higher risk of coronary heart disease, a 34% higher risk of stroke, and a 44% higher risk of developing heart disease compared to men without ED. - The link between diabetes and ED is especially strong, with men with type 2 diabetes being approximately three times more likely to develop erectile dysfunction. - Despite ED's predictive value for serious conditions including dementia, many men avoid seeking medical help due to shame, missing a critical window for early intervention.
- Cedars-Sinai investigators developed a blood filtering treatment that removes harmful sFlt-1 protein to manage severe early preeclampsia, a leading cause of premature birth and maternal death. - The treatment safely extended pregnancies by an average of 10 additional days in 16 women with early preeclampsia, potentially doubling the time to delivery after hospitalization. - The extracorporeal apheresis technique reduced blood sFlt-1 levels by 17 percent and slightly decreased blood pressure while allowing continued fetal growth during treatment. - Larger controlled trials are needed to confirm safety and effectiveness, as the current study's small size cannot fully address all safety concerns.
- Kairos Pharma has signed a term sheet to acquire CL-273, a pan-EGFR inhibitor, and CL-741, a c-MET inhibitor, from Celyn Therapeutics to target the multi-billion dollar lung cancer market. - The acquisition aims to strengthen Kairos's strategy of overcoming drug resistance in EGFR-mutant non-small cell lung cancer by combining EGFR and c-MET pathway inhibition. - CL-273 offers a 4-5 fold wider therapeutic window than existing therapies due to its wild-type-sparing profile, while CL-741 is Phase 1-ready for c-MET-driven solid tumors. - The deal is expected to close within three months, though Kairos faces financial constraints with only $5 million in cash as of November 2025.
- Abbott has received FDA clearance and CE Mark for its Amplatzer Piccolo Delivery System, designed specifically to treat patent ductus arteriosus (PDA) in premature infants weighing as little as two pounds. - The new delivery system simplifies PDA closure procedures by requiring only one catheter instead of multiple, with a shorter and softer design that enables more precise device positioning in tiny babies. - Patent ductus arteriosus affects approximately 20% of premature infants and involves a life-threatening opening between blood vessels in the heart that fails to close after birth. - The system works with Abbott's Amplatzer Piccolo Occluder, the world's first and only minimally invasive transcatheter treatment approved for PDA closure in premature infants.
- Ronde-cel demonstrated a 93% overall response rate and 76% complete response rate with 18-month median progression-free survival in third-line or later large B-cell lymphoma patients. - The dual-targeting CD19/CD20 CAR T-cell therapy achieved an 83% overall response rate in second-line patients, with 94% having primary refractory disease. - Safety profile showed no high-grade cytokine release syndrome and only 5% of patients experienced Grade 3 or higher immune effector cell-associated neurotoxicity syndrome. - Two pivotal trials are underway, including the first head-to-head CAR T-cell comparison trial against approved therapies.
